AGM Presentation
Released
Released
Announcement PDF
CCO AGM 2025
28 November 2025
(ASX: CCO)
STRONG REVENUE GROWTH
ACROSS THE BOARD IN FY25
CHANNEL STRATEGY
STRATEGIC PILLARS
Regional Sourcing
& Innovation
THE WORLD’S LEADING NATURAL RELAXATION COMPANY
- PACIFIC ISLAND
REGIONAL
SOURCING
- FIJI EXCELLENCE
IN QA & SERVICE
- CO2 EXTRACTION
- BLOCKCHAIN
TRACEABILITY
Direct to Consumer
Inc. Amazon
Profitable &
Scalable Retail
Wholesale (Bulk)
Ingredients
- AMAZON
USA & AU
- SALESFORCE
WEBSITES (FK,
TM and DN)
- HIGH-MARGIN,
HIGH-
AWARENESS DTC
FOCUS
- MAJOR RETAIL
- SUPPORTING
PHARMACY &
NUTRITION
- HIGH-EXPOSURE,
TRIAL & RESALE
TO MAINSTREAM
- AU & GLOBAL
- BEVERAGE & KAVA
SNACK BRANDS
- COMPLEMENTARY
MEDICINES
- CO-MANUFACTURE
& FLAVOUR HOUSES
- KAVA HOSPITALITY
REGIONAL SOURCING & INNOVATION
Serves as a roadmap to establishing a globally
competitive and sustainable kava supply
chain that supports quality standards,
innovation, regulatory improvements, and
market expansion.
The Calmer Co is well positioned to support a
regional supply chain given increased global
demand for kava which will further de-risk
against adverse weather events and any
anticipated pricing volatility.
Solomon Islands kava export pathway to Fiji
now open and strategic partners appointed in
Solomon Islands and PNG to support regional
supply.
STRONG GROSS MARGINS IN E-COMMERCE
Rapid growth in e-commerce revenues is driving robust gross margins. Additionally, online sales in
the USA have surged, fueled by the launch of new products such as flavoured kava shots
OUR RETAIL IS PROFITABLE AND SCALABLE
The involvement of both Woolworths and Coles enhances brand awareness and highlights widespread
consumer acceptance in Western markets, a trend that has the potential to be replicated in the USA
WHOLESALE CHANNEL EXPANDS
The Calmer Co has invested 15 years in developing a vertically integrated supply chain that is difficult
to replicate. We have also pioneered innovative wholesale product formats, including Kavaton and
high-concentration CO2 extracts. As the market leader supplying major distribution partner, we are
well positioned to capitalise on the growing kava trend.
TOTAL SALES UP 26%
$2,100,000
$1,800,000
$1,900,000
$2,402,000
$1,500,000
$1,600,000
$1,700,000
$1,800,000
$1,900,000
$2,000,000
$2,100,000
$2,200,000
$2,300,000
$2,400,000
$2,500,000
Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26
Global Sales by Quarter
Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26
The Calmer Co set a new sales record of
$2.4m in Q1, FY26. This represents a quarterly
growth rate of 26% vs Q4, FY25.
Retail sales are a growing category as Coles &
Woolworths expand their listings. Retail
comprised 48% of overall sales this quarter.
Wholesale is also an exciting growth channel with
kavaton and new CO2 high concentration
extracts in high demand from retail partners. The
wholesale channel set a new sales record with
$314k sales in September and accounted for
13% of total sales this quarter.
RETAIL SALES UP 68%
Total retail sales we up 68% to $1.15m
on a quarterly basis.
This growth was driven by Coles
expanding their listings and a full quarter
of sales via Woolworths.
The retail channel expands consumer
awareness of kava driving broader
adoption.
$525,000
$648,000
$684,000
$1,150,000
$0
$200,000
$400,000
$600,000
$800,000
$1,000,000
$1,200,000
Q2 2025 Q3 2025 Q4 2025 Q1 2026
Retail Sales by Quarter
Q2 2025 Q3 2025 Q4 2025 Q1 2026
USA SALES UP 21%
USA based sales were up 21% to $935k on a
quarterly basis.
This USA growth was driven by both online and
wholesale channels.
The wholesale channel set a sales record in
September as retail partners ordered kavaton
and high concentration CO2 Extract formats.
Broad consumer adoption of new product
formats in the USA in both ecommerce and
wholesale drives our US growth story.
$387,000
$305,000
$775,000
$935,000
$100,000
$200,000
$300,000
$400,000
$500,000
$600,000
$700,000
$800,000
$900,000
$1,000,000
Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26
USA Sales
Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26
CASH USED IN OPERATIONS DOWN 39%
$200
$300
$400
$500
$600
$700
$800
$900
$1,000
$1,100
$1,200
$1.5
$1.6
$1.7
$1.8
$1.9
$2.0
$2.1
$2.2
$2.3
$2.4
$2.5
Q2 25 Q3 25 Q4 25 Q126
Total Sales Net Cash Used in Operations
Net cash used in operations was $597k in Q1
which represents a significant 39% reduction vs
the prior quarter.
Inventory on hand at end Q1 was $2m.
Cash on hand was $1.37m assisted by
convertible note funding which secured $700k as
tranche one of a $1.4 million facility to support
wholesale inventory build and growth initiatives.
vs Q4 FY25
39%
$597k
Net Cash
Used in
Operations
Total Sales vs Cash Used in Operations
THE CALMER Co. IS A GLOBAL GROWTH
STORY
Kava is rapidly emerging as one of the world’s most sought-after
functional ingredients, gaining strong global recognition for its
natural calming benefits.
The Calmer Co achieved $8 million in revenue for FY25, an 86%
increase on FY24 and nearly fivefold growth in just two years.
In Q1 FY26, we reached a record $2.4 million in quarterly
revenue, with an annualised run rate now exceeding $10 million.
Break-even is now within reach.
In July, we launched an exciting new range of products in the
expanding U.S. kava market, with early results showing strong
consumer acceptance and promising growth ahead.
Zane Yoshida
Founder & CEO
The Calmer Co
Share your feedback
Discover